Does ACALABRUTINIB Cause Second primary malignancy? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Second primary malignancy have been filed in association with ACALABRUTINIB (CALQUENCE). This represents 0.1% of all adverse event reports for ACALABRUTINIB.
8
Reports of Second primary malignancy with ACALABRUTINIB
0.1%
of all ACALABRUTINIB reports
1
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From ACALABRUTINIB?
Of the 8 reports, 1 (12.5%) resulted in death, 1 (12.5%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
Yes, Second primary malignancy is listed as a known adverse reaction in the official FDA drug label for ACALABRUTINIB.
What Other Side Effects Does ACALABRUTINIB Cause?
Death (1,857)
Fatigue (536)
Headache (534)
Product dose omission issue (349)
Diarrhoea (320)
Fall (289)
Malignant neoplasm progression (285)
Contusion (270)
Dyspnoea (259)
Pneumonia (244)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ACALABRUTINIB Alternatives Have Lower Second primary malignancy Risk?
ACALABRUTINIB vs ACAMPROSATE
ACALABRUTINIB vs ACARBOSE
ACALABRUTINIB vs ACCUTANE
ACALABRUTINIB vs ACEBUTOLOL
ACALABRUTINIB vs ACECLOFENAC